Lisata Therapeutics, Inc. agreed to be acquired by Kuva Labs Inc. in a merger transaction where shareholders will receive $5.00 per share in cash plus contingent consideration, representing a significant liquidity event for the company.

On March 6, 2026, Lisata Therapeutics, Inc. entered into a Material Definitive Agreement, specifically an Agreement and Plan of Merger with Kuva Labs Inc. and Kuva Acquisition Corp. This agreement stipulates that Purchaser will commence a tender offer to acquire all issued and outstanding shares of Lisata's common stock at a price of $5.00 per share in cash, along with a contingent payment right. The transaction is subject to standard closing conditions, and this merger represents a strategic move to enhance shareholder value and broaden company capabilities. The merger deal positions Lisata for expansion and growth through this acquisition.

Real-time funding, M&A, exec moves & hiring — the signals that move deals

Lisata Therapeutics, Inc.

AI Executive Summary

Key Takeaways

Raw Filing Content

Related Filings (1)

Filing Overview

What This Means